Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Context Therapeutics Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "August 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for"
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/22/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
Docs: "Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024",
"March 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for"
02/14/2023 SC 13G Context Therapeutics Inc. reports a 7.3% stake in Context Therapeutics Inc.
02/06/2023 8-K Quarterly results
01/27/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/10/2023 SC 13G/A SABBY MANAGEMENT, LLC reports a 5% stake in Context Therapeutics Inc.
01/09/2023 SC 13G/A HIRSCHMAN ORIN reports a 0% stake in Context Therapeutics Inc.
01/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate",
"January 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for"
12/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer"
12/01/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024",
"Identification of CTIM-76,"
11/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/09/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/09/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/09/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/09/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "November 2022 Corporate Presentation Advancing Medicines for Female Cancers Important Notice and Disclaimers Except for"
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/27/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
09/27/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND",
"September 2022 Corporate Presentation Advancing Medicines for Female Cancers Forward Looking Statement Except for"
08/11/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/02/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/02/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models",
"2022 BRINGING CHANGE FOR FEMALE CANCERS"
06/03/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/03/2022 8-K Quarterly results
05/12/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy